Literature DB >> 7524906

Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy.

X Mariette1, J P Fermand, J C Brouet.   

Abstract

In order to assess the contamination with malignant cells of peripheral blood stem cell (PBSC) transplants used to support high-dose therapy in multiple myeloma (MM), we used the immunoglobulin heavy chain gene radioactive fingerprinting polymerase chain reaction (PCR) method to detect clonal cells in PBSC from 10 patients. The sensitivity of the technique allowed the detection of one clonal cell among 10(4) normal blood mononuclear cells. A clonal band was detected in 4 of 11 leukaphereses samples. The level of contamination was low because a clonal band could never be identified on ethidium bromide-stained agarose gels whose sensitivity is between 1 and 5%. The use of granulocyte-colony stimulatory factor (G-CSF) in combination with chemotherapy in three cases did not seem to increase the contamination of PBSC grafts; in one patient, G-CSF was used during a second course of leukapheresis which was free of detectable clonal cells whereas the first one performed after chemotherapy alone contained clonal cells. Thus, PBSC grafts may rarely be completely devoid of clonal potentially malignant cells but the level of contamination is much lower than in BM grafts. Whether graft contamination is an important adverse prognostic factor for patients with MM undergoing intensive treatment and autografting is still unsettled.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524906

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

1.  Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation.

Authors:  Wichard Vogel; Hans-Georg Kopp; Lothar Kanz; Hermann Einsele
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-23       Impact factor: 4.553

2.  Comparison of twin and autologous transplants for multiple myeloma.

Authors:  Asad Bashey; Waleska S Pérez; Mei-Jie Zhang; Kenneth C Anderson; Karen Ballen; James R Berenson; L Bik To; Rafael Fonseca; César O Freytes; Robert Peter Gale; John Gibson; Sergio A Giralt; Robert A Kyle; Hillard M Lazarus; Dipnarine Maharaj; Philip L McCarthy; Gustavo A Milone; Stephen Nimer; Santiago Pavlovsky; Donna E Reece; Gary Schiller; David H Vesole; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

Review 3.  Detection of minimal residual disease in multiple myeloma and acute leukaemia.

Authors:  M H Bakkus; N Juge-Morineau; J E van der Werff ten Bosch
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

4.  Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma.

Authors:  S Wuillème; A Lok; N Robillard; P Dupuis; V Stocco; H Migné; A Dusquesne; C Touzeau; M Tiab; M C Béné; P Moreau
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 5.  Multiple myeloma, high-dose treatment and autologous stem cell transplantation--current status.

Authors:  B Björkstrand
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

6.  Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.

Authors:  N Raje; R Powles; C Horton; B Millar; V Shepherd; G Middleton; S Kulkarni; T Eisen; J Mehta; S Singhal; J Treleaven
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.